Huons Group’s Pangen is expanding its cell-based activity analysis services after securing a new contract in this field.
Industry sources reported on Wednesday that Pangen has recently been commissioned by Huons to conduct bioassay services for liraglutide and semaglutide.
Cell-based activity analysis is a complex process that demands high-level expertise and cutting-edge technology at every stage. This includes selecting appropriate cell lines, determining drug concentrations, designing detection mechanisms, and interpreting results.
Pangen has honed its analytical capabilities through extensive research and development of various biopharmaceuticals, including erythropoietin (EPO) biosimilars. This experience has enabled the company to achieve high accuracy and reproducibility in its analyses, allowing it to offer tailored analytical services and bolster its competitive edge.
Building on this success, Pangen plans to significantly expand its cell-based activity analysis and analytical method validation services. The company aims to broaden its efficacy evaluation scope beyond biopharmaceuticals to encompass a wide range of medications.
A Pangen spokesperson stated that they’re currently expanding the cell-based activity analysis services. By leveraging the analytical expertise, built on the robust platform technology, it aims to enhance the clients’ development efficiency and provide support in acquiring reliable data.
It’s worth noting that Pangen has been developing its contract development and manufacturing organization (CDMO) services based on its proprietary core technology platform, PANGEN CHO-TECH™.
To date, Pangen has successfully completed over 140 CDMO service projects, securing contracts from numerous domestic and international companies. The company currently possesses 41 types of cell lines suitable for biopharmaceutical production, including 28 therapeutic protein-producing cell lines and 13 biosimilar antibody-producing cell lines.
